课题基金 / 基金详情

PHARMACOKINETICS OF RIBAVIRIN IN SUBJECTS WITH CHRONIC LIVER DISEASE

PHARMACOKINETICS OF RIBAVIRIN IN SUBJECTS WITH CHRONIC LIVER DISEASE
利巴韦林在慢性肝病患者中的药代动力学
批准号：
6281007
负责人：
STEVEN SCHENKER
金额：
$1.49万
依托单位：
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6281007
关键词：
chronic disease /disorder clinical research clinical trial phase I combination chemotherapy dosage drug screening /evaluation hepatitis C human subject human therapy evaluation immunotherapy interferons liver disorder chemotherapy microorganism disease chemotherapy pharmacokinetics ribavirin

项目摘要

项目成果

STEVEN SCHENKER的其他基金

相似基金

相关文献

中文摘要
翻译
干扰素治疗慢性病毒性肝炎疗效确切 只有大约20%的这类患者。利巴韦林还可以降低异常肝脏 慢性丙型肝炎的检测希望联合 干扰素和利巴韦林联合治疗将提高慢性粒细胞白血病的治疗潜力 个别药物。这项研究将比较单一的消除 不同肝病患者和正常对照组的利巴韦林剂量比较 因此，严重程度允许评估正确剂量的利巴韦林 慢性丙型肝炎患者的联合用药情况。
英文摘要
The treatment of chronic viral hepatitis with interferon is effective in only about 20% of such patients. Ribavirin can also lower abnormal liver tests in chronic hepatitis C. It is hoped that the combination of interferon and ribavirin therapy will improve the therapeutic potential of the individual drugs. This study will compare the elimination of a single dose of ribavirin in controls and patients with liver disease of varying severity thus permitting an assessment of the correct dose of ribavirin and of the drug combination in patients with chronic hepatitis C.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
FOOD RESTRICTION ON ACETAMINOPHEN METABOLISM & DISPOSITION
EFFECT OF POLYUNSATURATED LECITHIN ON LIVER FIBROSIS
FOOD RESTRICTION ON ACETAMINOPHEN METABOLISM & DISPOSITION
EFFECT OF POLYUNSATURATED LECITHIN ON LIVER FIBROSIS
海外基金